A participant in a decentralized trial signs an amended consent form from her kitchen table, and three weeks later a monitor can't confirm which version she reviewed. That gap between remote convenience and audit-ready documentation separates a functional eConsent tool from one built for real decentralized trial operations. This comparison reviews six eConsent platforms for decentralized clinical trials, evaluated on remote consent, re-consent version control, and eClinical stack integration, with Viedoc's eConsent software leading the field.
You're running sites where a meaningful share of participants never set foot in a clinic before consenting, without an investigator standing beside them to answer a question in the moment. Protocol amendments arrive mid-study, and every affected participant needs to move to the new consent version without a documentation gap or a stalled visit. A platform that treats consent as a simple signature capture, rather than a comprehension and version-control problem, becomes a liability the first time a monitor asks who signed what and when.
Generic e-signature tools solve the signing step but not the informed part of informed consent: no multimedia content, no comprehension checks, and no connection to the EDC holding the rest of the participant's data. Enterprise platforms built for large, site-based Phase III programs often bring more configuration overhead than a lean sponsor or CRO team running a decentralized study needs. The platforms below were reviewed for remote and hybrid consent handling, protocol-driven re-consent, and integration depth, without adding a separate vendor relationship just to stay audit-ready.
Best eConsent solutions: quick comparison
| Platform | Product / module | Overview |
|---|---|---|
| Viedoc | eSignature (eConsent) | Consent embedded in the Viedoc suite, remote or in-clinic, across 7,500-plus studies with Part 11 built in. |
| Medidata | Medidata Consent | Configurable workflows unified with Rave EDC and eCOA, with pediatric assent and eIDAS signatures. |
| Signant Health | SmartSignals eConsent | PDF-based or interactive consent with comprehension quizzes, self-service or fully managed. |
| Medable | Total Consent | Standalone SaaS eConsent for decentralized trials, with e-signature and wet-ink upload across 120-plus locales. |
| Castor | Castor eConsent | Modular consent with video visits and recruitment tools, native to Castor's EDC and eCOA. |
| Medrio | Medrio eConsent | Consent within Medrio's unified platform, in-clinic and remote signing plus wet-ink upload. |
These six eConsent platforms represent the most evaluated options for decentralized clinical trials, reviewed across remote consent workflows, re-consent version control, comprehension support, and integration depth.
1. Viedoc
Viedoc's eConsent software supports informed consent within the Viedoc eClinical suite, letting participants review and sign documents remotely or on site, on the device of their choice, across studies run in 75-plus countries. Signing happens inside the same environment as Viedoc EDC, Viedoc TMF, and Viedoc Me, so a signed document is immediately reflected in the participant's record rather than sitting in a separate consent system that a data manager has to reconcile by hand. That matters most for teams running decentralized and hybrid designs, where a participant might never visit a physical site before their first consent event.
For CROs managing several concurrent decentralized studies, the same no-code Designer used to build eCRFs configures consent workflows, so amendments and re-consent triggers don't require a vendor programming ticket. Sponsors and QA teams get a complete, time-stamped audit trail from document issuance through signature completion, with document access governed by role-based permissions across the suite.
Viedoc's eConsent workflow is built to meet FDA 21 CFR Part 11, ICH GCP, GDPR, and HIPAA requirements, and runs on infrastructure certified to ISO 27001 and SOC 2. The platform is backed by 24/7 support across Viedoc's global offices, so a re-consent issue discovered outside business hours in one region doesn't have to wait for the next working day somewhere else.
-
Study scale: 8,000-plus global studies, with a 100% FDA inspection pass rate.
-
Compliance: 21 CFR Part 11, ICH GCP, GDPR, and HIPAA, on ISO 27001- and SOC 2-certified infrastructure.
-
Suite integration: Consent, data capture, ePRO, and document management run in one environment, with no manual reconciliation between systems.
-
Support: 24/7 support across global offices.
2. Medidata
Medidata offers Medidata Consent, a configurable consent solution built to reduce site burden by operating as a unified part of Rave EDC, RTSM, and eCOA rather than a separate login. The platform supports pediatric assent with age-cohort-specific workflows, multi-arm trial designs, and re-consenting, and it automates notifications when a re-consent is required so teams can track completion proactively. For global studies, Medidata Consent supports eIDAS-compliant electronic signatures and a hybrid paper-to-digital upload option for regions that still require wet-ink signatures. The solution is positioned within Medidata's broader Patient Experience suite alongside eCOA and myMedidata, and integrates real-time video visits into the consent process itself. Medidata markets the platform to large biopharma, emerging biotech, and MedTech sponsors running studies of varying complexity.
3. Signant Health
Signant Health offers SmartSignals eConsent, available as either a simplified PDF-based consent process or a fully interactive, multimedia experience. The interactive option includes embedded video and audio content, comprehension quizzes, and the ability for participants to flag sections of the consent form to discuss with an investigator before signing. Both options support remote, on-site, and hybrid studies, and Signant Health offers self-service implementation for teams that want direct control, alongside an add-on project delivery service for teams that prefer a managed build. Sponsors get real-time visibility into study progress alongside a complete audit trail. The platform integrates with Signant's own eCOA and RTSM solutions and with other eClinical systems, and its tiered licensing is designed to scale from Phase I studies through global Phase III programs.
4. Medable
Medable offers Total Consent, a standalone SaaS eConsent platform purpose-built for decentralized and hybrid clinical trials. The platform allows sponsors and CROs to customize consent content and branding across more than 120 locales while meeting local regulatory requirements, and it supports both electronic signatures and print-to-sign templates for regions that require wet-ink consent. Total Consent includes authoring tools for building consent content directly, along with training resources and a rapid onboarding option aimed at accelerating deployment across new studies. Medable has deployed Total Consent and its broader decentralized trial platform, which also covers eCOA, remote screening, and telehealth, across more than 300 digital and decentralized trials since the company's founding in 2015, and markets the platform to sponsors and CROs running global, patient-centered trial designs.
5. Castor
Castor offers Castor eConsent as part of its unified EDC, eCOA, and decentralized trial platform. The module supports remote enrollment through a customizable recruitment portal, pre-screening questionnaires, and video-based consent visits, all built into the same interface participants use for the rest of the study. Consent data captured through the module updates directly in Castor's EDC record, and the platform supports multiple consent forms per site with version control so sites always use the current, approved iteration of the informed consent form (ICF). New ICF versions can be created quickly by duplicating an existing form. Castor eConsent is 21 CFR Part 11 compliant, includes multi-factor authentication and a full audit trail, and is available as a standalone module or packaged with Castor's broader eClinical suite.
6. Medrio
Medrio offers Medrio eConsent as part of its unified eClinical platform, alongside its EDC, ePRO, RTSM, and eTMF modules. The solution supports both electronic and paper-based consent within a single web-based interface, allowing sites to consent participants in-clinic using tablet workflows or remotely through email and a secure participant portal. Medrio eConsent lets sites upload wet-ink signed paper forms where local regulation still requires them, keeping digital storage and audit benefits even for regions that haven't moved fully to electronic signing. The platform is designed to accommodate both in-clinic and bring-your-own-device consent, reducing the need for participants to learn a new device just to complete the consent process. Medrio positions the module for early-phase, MedTech, and CRO-run studies alongside its broader Phase I through Phase III platform.
What to look for in eConsent solutions for decentralized clinical trials
Remote consent completion without losing comprehension
A decentralized trial's consent process has to work when the participant is at home, not in a room with an investigator ready to answer a question. This matters more for eConsent than for most eClinical modules, because informed consent is a legal and ethical requirement, not just a data-collection step.
Best-in-class platforms combine remote signing with multimedia content and comprehension checks that flag sections a participant found confusing before they sign. Some also support live video visits during the consent conversation, closing the gap between remote and in-person experience. A platform that only digitizes the signature, without addressing comprehension, shifts the compliance risk to a different audit finding: a signed form with no evidence of understanding.
Re-consent and ICF version control across a live study
Protocol amendments trigger re-consent, and in a multi-country decentralized trial, different countries often need different form versions running at once. How a platform routes participants to the correct version and blocks an outdated one is one of the most operationally significant features in eConsent, and one that's easy to underestimate in a vendor demo.
Look for automatic version control that flags every affected participant, tracks re-consent completion at the site and study level, and blocks superseded forms. A platform that requires a coordinator to manually track versions at scale will eventually miss one, and that gap becomes a monitoring finding.
Integration with EDC, ePRO, and the rest of the trial stack
A standalone eConsent tool that doesn't talk to the system holding the rest of the participant's data creates a reconciliation task for every signature. In a decentralized trial, where participants already juggle multiple remote touchpoints, an extra disconnected login adds friction for the population most likely to drop out.
The strongest platforms treat consent as one workflow inside the same environment as data capture and, where relevant, ePRO software, so a signed consent unlocks the next step without a manual handoff between systems.
Regulatory coverage across the regions your trial actually runs in
Decentralized trials often span countries with different consent rules, from wet-ink signature requirements in some jurisdictions to pediatric assent rules in others. A platform needs 21 CFR Part 11 compliance as a baseline, but for global studies, GDPR coverage and hybrid paper-to-digital workflows matter just as much.
Confirm that compliance claims are documented on the vendor's own site, and check whether hybrid wet-ink support is a genuine feature or a manual workaround.
How to choose the right eConsent solution for decentralized clinical trials
Step 1: Map your trial's consent complexity before comparing vendors
Start with your protocol, not a vendor shortlist. A single-country Phase II study with adult participants has different consent needs than a multinational trial with pediatric cohorts and mixed electronic and wet-ink requirements.
Step 2: Decide how much of the consent experience needs to be interactive
A simplified, PDF-based flow may be adequate for a straightforward study, while a trial with a more vulnerable population may need multimedia content and comprehension testing. Overbuying interactive features for a simple study adds cost without improving compliance.
Step 3: Assess how re-consent is actually handled, not just whether it's supported
Ask each vendor what happens when an amendment goes live mid-study: how participants are identified, how the correct version is routed, and what a monitor sees in the audit trail. Vague answers signal manual work dressed up as a feature.
Step 4: Scrutinize the integration path with your EDC and ePRO systems
Determine whether consent data flows automatically into your data capture system or requires a separate integration project, and ask what happens when a participant signs remotely outside business hours. Nightly batch syncing reintroduces the delay decentralized trials are meant to eliminate.
Step 5: Choose a platform that treats consent as part of one connected trial, not a bolted-on module
If your team already runs or is evaluating Viedoc for EDC, ePRO, or eTMF, extending to Viedoc's eConsent software keeps consent, data capture, and participant communication inside one audit trail instead of adding a fourth vendor relationship. Book a demo to see how consent and data capture connect in practice for your study design.
Frequently asked questions
What is the best eConsent platform for decentralized clinical trials?
Viedoc's eConsent software is the strongest overall choice for decentralized clinical trials, because consent runs inside the same suite as EDC, ePRO, and eTMF rather than as a standalone tool a team has to reconcile manually. Medable is a strong alternative for teams that specifically want a standalone, DCT-native eConsent platform decoupled from a broader EDC relationship. Signant Health is worth evaluating for studies that need the most feature-rich, multimedia consent experience with dedicated comprehension testing tools.
What should I look for when choosing an eConsent platform?
Prioritize remote consent completion with genuine comprehension support, not just a digitized signature. Confirm how the platform handles re-consent and ICF version control across a live study, and check whether consent data flows automatically into your EDC or requires a separate integration. Regulatory coverage across every country your trial runs in, including hybrid wet-ink support where required, should be documented on the vendor's own site rather than asserted only in a sales conversation. Also ask how the platform reports on consent status, since a sponsor running multiple sites needs visibility into who has and hasn't completed each version.
How long does it take to deploy an eConsent workflow on a modern platform?
Timelines depend on study complexity and how much custom content is needed, but a straightforward, self-service eConsent build on a no-code platform can typically be configured in days rather than months. More complex builds involving multimedia content, comprehension testing, or multi-country form variants take longer, particularly where a managed implementation service is used instead of self-service configuration. A mid-study amendment that requires a new consent version should generally take far less time than the original build, since the underlying study structure and integrations are already in place. Ask any vendor for a specific timeline tied to your protocol's actual consent complexity rather than a generic marketing figure.
Does eConsent work for trials that still require wet-ink signatures in some regions?
Yes, several platforms, including Viedoc, Medidata, Medable, and Medrio, support hybrid workflows where participants in regions requiring wet-ink signatures can sign a paper form that is then uploaded and stored digitally alongside electronically signed consents from other sites. This keeps a single, centralized, audit-ready consent record even when signature methods vary by country. Confirm during evaluation whether this hybrid support is a native workflow or a manual upload workaround, since the operational burden differs significantly between the two.
How does eConsent support re-consent when a protocol is amended mid-study?
A well-built eConsent platform flags every participant affected by an amendment, routes them automatically to the updated consent version, and tracks completion at both the site and study level. This prevents sites from accidentally using a superseded version and gives sponsors real-time visibility into re-consent progress across every site. Platforms that lack automated version routing put the burden of tracking which participants are on which version onto site staff, which becomes harder to manage as a study scales, and harder still across multiple concurrent studies.
Making the right eConsent choice for decentralized clinical trials
The eConsent platforms reviewed here share a common shift: consent is treated as a participant-facing experience that has to work without an investigator beside the patient, not just a paperwork step. Approaches range from standalone, DCT-native consent tools to modules embedded within a broader eClinical suite, and the global eClinical software market, estimated at more than $11 billion in 2025 and growing at roughly 14% annually, reflects how central this category has become.
The right fit depends on your trial's consent complexity, country footprint, and existing eClinical stack. A team already running EDC and ePRO on one platform generally benefits from a connected decentralized clinical trials consent workflow, while a team without one may prioritize a standalone specialist tool. US sponsors tend to weight deployment speed most heavily, while EMEA and APAC teams often weight regulatory documentation more heavily.
Switching vendors mid-study carries its own validation burden, and every added eClinical vendor introduces a point of integration failure.
Why Viedoc is the best eConsent choice for decentralized clinical trials
If you're running a decentralized or hybrid trial, the strongest argument for Viedoc's eConsent software is that it isn't a separate system bolted onto your trial technology. Consent runs inside the same suite as Viedoc EDC, Viedoc Me, and Viedoc TMF, backed by a platform that has powered 7,500-plus global studies with a 100% FDA inspection pass rate.
Operationally, that means the same no-code Designer your team already uses to build eCRFs configures consent workflows and re-consent triggers, without a vendor programming ticket for every amendment. Unlimited user seats and transparent, study-based licensing mean adding eConsent to an existing Viedoc study doesn't introduce a new per-user cost structure to negotiate, and Viedoc's 24/7 support covers consent issues the same way it covers every other part of the suite.
On compliance, Viedoc's eConsent workflow meets FDA 21 CFR Part 11, ICH GCP, GDPR, and HIPAA requirements, running on ISO 27001- and SOC 2-certified infrastructure, with a complete, time-stamped audit trail from document issuance through signature.
If you want to see how consent, data capture, and participant engagement work together in one connected trial rather than four separate vendor relationships, book a demo or request a proposal and we'll walk through it against your own study design.
